Behavioral factors to modulate immunotherapy efficacy in cancer

Immune checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 therapies, are used to (re)activate the immune system to treat cancer. Despite promising results, a large group of patients does not respond to checkpoint inhibition. In the vulnerability-stress model of behavioral medicine, behaviora...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongerius, C., Vermeulen, L., van Egmond, M., Evers, A. W. M., Buffart, L. M., Lenos, K. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800824/
https://www.ncbi.nlm.nih.gov/pubmed/36591246
http://dx.doi.org/10.3389/fimmu.2022.1066359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800824/
https://www.ncbi.nlm.nih.gov/pubmed/36591246
http://dx.doi.org/10.3389/fimmu.2022.1066359

Ejemplares similares